News about "Pfizer"

Pfizer-Valneva Lyme Vaccine Shows Strong Phase-III Efficacy

Pfizer and Valneva’s Lyme disease vaccine candidate showed over 70 percent efficacy in phase-III trials in individuals aged five years and above, with a strong safety profile, as Pfizer prepares for regulatory submissions, marking a key step towards potential approval.

Pfizer | 24/03/2026 | By News Bureau

Pfizer Joins BaseLaunch Biotech Incubator

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures.

Pfizer | 12/02/2026 | By News Bureau |  232

Pfizer Launches Cost Savings Programme on TrumpRx

Pfizer has rolled out a new cost-savings initiative, TrumpRx, aimed at making medicines more affordable for US patients. The programme covers over 30 brands across major therapy areas and reinforces the company’s commitment to lowering drug prices under its landmark agreement with the Trump administration.

Pfizer | 07/02/2026 | By News Bureau |  136

UK Industry Body Finds Sanofi in Breach Over RSV Therapy Claims Against Pfizer

A UK pharmaceutical industry watchdog has ruled that Sanofi breached the country’s code of practice by making misleading claims about its respiratory syncytial virus (RSV) therapy in comparison with a rival product from Pfizer.

Pfizer | 04/02/2026 | By Darshana |  159

Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss

Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.

Pfizer | 04/02/2026 | By News Bureau |  239

Pfizer Reports Improved Response Rates with BRAFTOVI Regimen in Metastatic Colorectal Cancer

New data from the BREAKWATER study show that Pfizer’s BRAFTOVI-based regimen significantly improved response rates in patients with BRAF V600E–mutant metastatic colorectal cancer, supporting the potential use of flexible chemotherapy backbones.

Pfizer | 12/01/2026 | By News Bureau |  107

Pfizer and Cipla Form Exclusive Marketing Partnership for Select Brands in India

Pfizer and Cipla have joined forces in an exclusive marketing and distribution agreement for select brands in India. The collaboration aims to improve access and availability of these key medicines, ensuring patients across the country benefit from a wider reach and streamlined supply.

Pfizer | 19/12/2025 | By News Bureau |  106

Adaptive Biotechnologies Signs Two Immune Receptor Licensing Deals with Pfizer

Adaptive Biotechnologies has signed two immune receptor licensing agreements with Pfizer, covering a T-Cell Receptor (TCR) discovery collaboration in rheumatoid arthritis and access to Adaptive’s proprietary TCR-antigen datasets for immunology R&D.

Pfizer | 16/12/2025 | By News Bureau |  178

Yao Pharma and Pfizer Sign Exclusive Collaboration Deal

Yao Pharma has entered into an exclusive global licensing agreement with Pfizer, granting rights to develop, manufacture, and commercialise its oral small-molecule GLP-1 receptor agonists, including lead candidate YP05002. The partnership aims to advance next-generation metabolic therapies with worldwide reach.

Pfizer | 10/12/2025 | By Akanki |  100

US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer

PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).

Pfizer | 24/11/2025 | By Dineshwori |  122